Bernard-Soulier syndrome (BSS) is a rare bleeding disorder characterized by giant platelets, thrombocytopenia, and a prolonged bleeding time. It is caused by homozygous defects in the glycoprotein (GP) Ib/IX/V complex, which is the receptor for the von Willebrand factor. We examined a Turkish patient with suspected BSS to identify a molecular basis. Flow cytometric analysis revealed that platelet GPIbα and GPIX expression was markedly reduced and DNA sequence analysis showed a homozygous N45S missense mutation in the GPIX gene. Haplotype analysis revealed that the family had the same disease haplotype associated with the GPIX N45S commonly found in Northern European BSS. This is the first non-Caucasian Turkish BSS case due to GPIX N45S and is likely the result of a recurrent mutational event.

Kunishima S, Kamiya T, Saito H: Genetic abnormalities of Bernard-Soulier syndrome. Int J Hematol 2002;76:319–327.
Kunishima S, Saito H: Congenital macrothrombocytopenias. Blood Rev 2006;20:111–121.
Lanza F: Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy). Orphanet J Rare Dis 2006;1:46.
Lopez JA, Andrews RK, Afshar-Kharghan V, Berndt MC: Bernard-Soulier syndrome. Blood 1998;91:4397–4418.
Berndt MC, Shen Y, Dopheide SM, Gardiner EE, Andrews RK: The vascular biology of the glycoprotein Ib-IX-V complex. Thromb Haemost 2001;86:178–188.
Lopez JA: The platelet glycoprotein Ib-IX complex. Blood Coagul Fibrinolysis 1994;5:97–119.
Liang HP, Morel-Kopp MC, Clemetson JM, Clemetson KJ, Kekomaki R, Kroll H, Michaelides K, Tuddenham EG, Vanhoorelbeke K, Ward CM: A common ancestral glycoprotein (GP) 9 1828A>G (Asn45Ser) gene mutation occurring in European families from Australia and Northern Europe with Bernard-Soulier syndrome (BSS). Thromb Haemost 2005;94:599–605.
Kunishima S, Lopez JA, Kobayashi S, Imai N, Kamiya T, Saito H, Naoe T: Missense mutations of the glycoprotein (GP) Ibb gene impairing the GPIb α/b disulfide linkage in a family with giant platelet disorder. Blood 1997;89:2404–2412.
Kunishima S, Miura H, Fukutani H, Yoshida H, Osumi K, Kobayashi S, Ohno R, Naoe T: Bernard-Soulier syndrome Kagoshima: Ser 444→stop mutation of glycoprotein (GP) Ibα resulting in circulating truncated GPIbα and surface expression of GPIbβ and GPIX. Blood 1994;84:3356–3362.
Wright SD, Michaelides K, Johnson DJ, West NC, Tuddenham EG: Double heterozygosity for mutations in the platelet glycoprotein IX gene in three siblings with Bernard-Soulier syndrome. Blood 1993;81:2339–2347.
Sae-Tung G, Dong JF, Lopez JA: Biosynthetic defect in platelet glycoprotein IX mutants associated with Bernard-Soulier syndrome. Blood 1996;87:1361–1367.
Donner M, Karpman D, Kristoffersson AC, Winqvist I, Holmberg L: Recurrent mutation Asn45→Ser of glycoprotein ix in Bernard-Soulier syndrome. Eur J Haematol 1996;57:178–179.
Koskela S, Javela K, Jouppila J, Juvonen E, Nyblom O, Partanen J, Kekomaki R: Variant Bernard-Soulier syndrome due to homozygous Asn45Ser mutation in the platelet glycoprotein (GP) IX in seven patients of five unrelated Finnish families. Eur J Haematol 1999;62:256–264.
Okan V, Araz M, Camci C, Aktaran S, Sahin A, Buyukberber S, Bakir K, Cakmak EA: Bernard-Soulier syndrome in a Turkish family. Int J Clin Pract 2002;56:546–548.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.